Addex Therapeutics
ADXN
7 hedge funds and large institutions have $1.39M invested in Addex Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
470% more capital invested
Capital invested by funds: $243K → $1.39M (+$1.14M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.2% more ownership
Funds ownership: 0.06% → 0.26% (+0.2%)
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.77M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$153K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$49.1K |
| 4 |
VF
Virtu Financial
New York
|
+$36.4K |
| 5 |
Jane Street
New York
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.1K |
| 2 |
Renaissance Technologies
New York
|
-$14K |
| 3 |
SG
StoneX Group
New York
|
-$9.45K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.15K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $1.11M | +$5.77M | +228,435 | +423% |
|
|
ECM
2
Endurant Capital Management
San Mateo,
California
| $114K | +$153K | +6,037 | New |
|
|
OMC
3
Old Mission Capital
Chicago,
Illinois
| $62.2K | +$49.1K | +1,945 | +145% |
|
|
VF
4
Virtu Financial
New York
| $41K | +$36.4K | +1,440 | +204% |
|
|
5
Citadel Advisors
Miami,
Florida
| $32.5K | -$8.84K | -350 | -17% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $14.3K | -$72.1K | -2,853 | -79% |
|
|
7
Jane Street
New York
| $11K | +$14.7K | +583 | New |
|
|
8
Renaissance Technologies
New York
| – | -$14K | -1,095 | Closed |
|
|
SG
9
StoneX Group
New York
| – | -$9.45K | -750 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$9.15K | -726 | Closed |
|
ADXN Hedge Fund Activity: Q1 2023 in Review
7 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q1 2023, worth a combined $1.39M — up 470% from $243K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADXN and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was NEA Management Company, adding an estimated $5.77M. The largest seller was Susquehanna International Group, cutting an estimated $72.1K.
- 7 institutional investors held Addex Therapeutics (ADXN) as of Q1 2023, down from 8 in Q4 2022.
- Funds reported $1.39M of Addex Therapeutics stock for Q1 2023, up 470% quarter-over-quarter.
- 2 funds opened new Addex Therapeutics positions in Q1 2023 and 3 closed out, a net change of -1 holder.
- The largest Addex Therapeutics buyer in Q1 2023 was NEA Management Company, an estimated $5.77M added.
- The largest Addex Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $72.1K sold.
Based on aggregated 13F filings for Q1 2023.